Brought to you by 
Series G raises $38mm for Broncus Technologies
08 Dec 2008
Executive Summary
A few months after withdrawing its IPO, emphysema device developer Broncus Technologies is looking to venture capital again, raising $38mm in its Series G round led by first-time backer Ares Life Sciences, which put in $25mm and contributes a new board member. Also participating were existing investors including Abingworth, Bio*One, Charter Ventures, HBM BioVentures, JAIC America, Menlo Ventures, Pac-Link Ventures, Saints Capital, and Sightline Ventures. Broncus will use the money to complete the pivotal clinical trial for its minimally invasive Airway Bypass procedure, which helps release trapped air in the lungs.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series G raises $38mm for Broncus Technologies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice